🎄🌟 🎉 Wishing our readers a Merry Christmas and a Happy New Year filled with new possibilities! 🎄🌟 🎉
07 October 2024 | News
To enhance efficiency and improve traceability during the fill & finish process and product distribution
BD (Becton, Dickinson and Company), a leading global medical technology company in the US, and Swiss firm ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech startups, have announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.
The collaboration aims to pilot an RFID-based solution created by BD to improve manufacturing process efficiency, and provide traceability of individual units. This solution will benefit ten23 health and its customers by ensuring a higher traceability throughout both the manufacturing process and the supply chain.
The new traceability solution, branded BD iDFill Individual Prefillable Syringe Identification, involves equipping each PFS with an RFID tag encoded with a unique serial number called the Container Unique Identifier (CUID). This CUID can be scanned at various stages of the manufacturing process, from filling to secondary packaging or any further assembly.
By linking the drug code, filling batch, timestamps, and other relevant data with the CUID, the solution provides full container traceability and enables multiple applications, including automated reconciliation, mix-up prevention, and investigation management. This system also helps to quickly identify and trace individual units during production and beyond.
By focusing on individual units instead of batches, BD iDFill offers greater process visibility and efficiency. Furthermore, positioning the primary container as a bridge between separate process unit operations – such as filling and inspection - enables ten23 health to leverage the significant potential of existing process data and opens up new possibilities for advanced manufacturing applications both on-site and beyond.